Strong Merck stock trades close to a 52-week high as cancer vaccine data lift outlook
Published on 08/25/2026 at 07:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co., Inc. (US58933Y1055) stock is trading close to the top of its 52-week range in late August 2026 as investors reassess the companys oncology trajectory following positive late-stage melanoma vaccine data and a sharp recent rerating of the shares.
Recent market commentary dated August 24, 2026 highlighted that Merck stock opened at $152.43 on the New York Stock Exchange and was quoted at $152.85 later that morning, leaving the price just below a 52-week high of $154.49 and underscoring the strength of the latest move after the melanoma news according to a detailed stock quote overview.
Melanoma vaccine data drive a major rerating
Per recent coverage dated August 24, 2026, Merck reported that its personalized cancer vaccine for high-risk melanoma patients delivered positive Phase 3 results when combined with the immunotherapy Keytruda, improving recurrence-free survival and distant metastasis-free survival versus Keytruda alone in a 1,137-patient study as summarized in a melanoma vaccine report.
Market reports on August 19, 2026 noted that on the day the Phase 3 data were highlighted, Merck shares closed up 12.5 percent, adding $43 billion in market value in a single session and marking one of the biggest one-day moves in the companys history based on a detailed account of the vaccine trial reaction.
Analyst commentary cited in the same reporting indicates that one major bank lifted its 12-month price target on Merck stock to $160 from $140 while another raised its target to $150, reflecting higher confidence in Mercks earnings power and valuation following the melanoma vaccine success.
Oncology growth supports higher valuations
Beyond the headline move in the share price, recent analysis dated August 24, 2026 pointed out that Merck stock was trading at $152.54 and had gained 47.07 percent year to date, supported by continued expansion in oncology revenue in a broader discussion of large-cap biopharma performance.
The same analysis noted that sales of the Keytruda family of products reached $8.4 billion in the second quarter of 2026, representing 4 percent growth compared with the prior-year quarter, signaling that even from a high base the immuno-oncology franchise continues to expand.
For investors, the combination of a 47.07 percent year-to-date stock gain, a share price hovering at $152.85 versus a 52-week high of $154.49 and a 4 percent year-over-year increase in Keytruda-family sales to $8.4 billion in the second quarter of 2026 underscores how much of Merks valuation now rests on oncology execution.
Regulatory and policy headwinds form a counterweight
While the oncology pipeline and vaccine data have been clear positives, recent legal developments highlight a challenging policy backdrop for high-cost medicines in the United States.
A court decision reported on August 24, 2026 stated that a federal judge rejected Mercks challenge to the Medicare Drug Price Negotiation Program, finding that the companys participation in related Medicare and Medicaid arrangements under the Inflation Reduction Act framework was voluntary, which could increase long-term pricing pressure on selected drugs.
At the same time, broader sector coverage noted that the positive melanoma vaccine readout not only helped re-rate Merck stock but also contributed to sharp moves in partners and peers, with related mRNA vaccine developers posting triple-digit year-to-date gains after the Phase 3 data were shared.
Keytruda and the melanoma vaccine program
The latest catalyst centers on Mercks long-running collaboration to develop a personalized mRNA-based cancer vaccine that is given alongside Keytruda in high-risk melanoma patients whose tumors have been surgically removed.
According to recent summaries dated August 25, 2026, the Phase 3 trial enrolled 1,137 volunteers and demonstrated that the personalized vaccine, when combined with Keytruda, reduced the risk that melanoma would return or spread compared with Keytruda alone, with the companies earlier five-year follow-up data from a smaller study noting a 49 percent reduction in the chance of recurrence or metastasis when the vaccine was added to Keytruda.
This program is strategically important because it could expand Keytrudas reach into earlier-stage disease and potentially support combination strategies in other cancers, reinforcing Mercks leadership in immuno-oncology just as generic and biosimilar competition draws closer later in the decade.
Merck stock level and valuation context
Intraday snapshots on August 24, 2026 showed Merck stock trading at $152.85 on the New York Stock Exchange, a 0.03 percent increase compared with the previous closing price of $152.55, with a one-year price range stretching from a low of $77.58 to a high of $154.49.
The same quote overview highlighted a market capitalization of $376.37 billion as of August 24, 2026, illustrating how the recent 12.5 percent single-day rally and 47.07 percent year-to-date advance have lifted Mercks equity value.
With the current price essentially touching the top of the 52-week band at $154.49 and Keytruda-family sales growing 4 percent year over year to $8.4 billion in the second quarter of 2026, the numbers signal that investors are willing to pay a higher multiple for Merck stock as long as oncology growth and pipeline execution stay on track.
Keytruda as a flagship therapy
Keytruda, Mercks flagship immune checkpoint inhibitor, sits at the center of the companys growth strategy, spanning indications from melanoma and lung cancer to a wider range of solid tumors.
Recent oncology commentary emphasized that the drug has become one of the largest-selling medicines globally, and the 4 percent year-over-year sales increase to $8.4 billion in the second quarter of 2026 reinforces its role as a key earnings driver even as the company invests in new indications and combination regimens.
The combination of Keytruda with the personalized melanoma vaccine showcased in the 1,137-patient Phase 3 trial provides a template for how Merck may seek to extend the life cycle of its immunotherapy franchise through synergistic technologies like mRNA-based vaccines.
Stock positioning and investor takeaway
For investors, the current setup involves a stock that has risen 47.07 percent year to date to $152.54, sits within a narrow band of its 52-week high at $154.49 and benefits from oncology revenue rising 4 percent year over year to $8.4 billion in the second quarter of 2026, but that also faces legal and policy uncertainty regarding future drug pricing.
That combination of strong execution in oncology, a record-setting single-day gain of 12.5 percent that added $43 billion to the companys market value on the melanoma data day and a large-cap valuation of $376.37 billion as of August 24, 2026 provides a clear numerical frame for how Merck stock is currently positioned in the biopharmaceutical landscape.
Go deeper
More on Merck stock and its oncology strategy can be found in recent detailed market and science coverage that explores the latest melanoma vaccine data, the trajectory of Keytruda-family sales and the implications of US drug pricing reforms for large-cap pharmaceutical companies.
Keytruda-driven oncology portfolio
Merck has built a broad oncology portfolio around Keytruda, including indications in melanoma, non-small cell lung cancer, head and neck cancers and other tumor types, with ongoing research programs testing combinations with chemotherapy, targeted therapies and novel platforms such as personalized mRNA vaccines.
The melanoma vaccine partnership showcased in the 1,137-patient Phase 3 trial is one representative example of how Merck is leveraging external innovation to reinforce Keytrudas position, complementing internal pipeline assets in immuno-oncology, hematology and precision oncology that collectively aim to sustain revenue growth beyond the patents on current indications.
Merck stock and current market level
As of August 24, 2026, Merck stock was quoted at $152.85 on the New York Stock Exchange, a 0.03 percent gain versus the previous close at $152.55, with a 52-week trading range between $77.58 and $154.49 and a reported market capitalization of $376.37 billion.
Those figures highlight that Merck stock is trading close to its 52-week high in late August 2026, reflecting the markets response to the 12.5 percent rally on the melanoma vaccine news, the 47.07 percent year-to-date gain and the ongoing 4 percent year-over-year growth in Keytruda-family sales to $8.4 billion in the second quarter of 2026.
Fact box
Company: Merck & Co., Inc.
ISIN: US58933Y1055
Ticker: MRK
Exchange: New York Stock Exchange (primary listing)
Price (as of August 24, 2026, 11:11 a.m. ET): $152.85 USD
Market cap: $376.37 billion (as of August 24, 2026)
Sector / Industry: Pharmaceuticals / Biotechnology
Index membership: S&P 500
